Pmel-1 transgenic CD8+ T-cells expanded ex vivo with either idelalisib (PI3K-δ) or eganelisib (PI3K-γ) showed enhanced in vivo tumor control against a B16F10 melanoma (median survival 70 days and ~60 days, respectively) vs control CD8+ cultures (30 days) (113). This evidence concerns the gene CD8A and melanoma.